Scilex (SCLX) Competitors

Immunic has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Immunic's return on equity.

Immunic has higher earnings, but lower revenue than Scilex. Immunic is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

51.8% of Immunic shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Comparatively, 4.5% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Immunic's average media sentiment score of 0.00 equaled Scilex'saverage media sentiment score.

Immunic currently has a consensus price target of $47.57, indicating a potential upside of 235.70%. Given Immunic's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunic is more favorable than Scilex.

Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Scilex has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 145.33%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Minerva Neurosciences is more favorable than Scilex.

In the previous week, Minerva Neurosciences had 6 more articles in the media than Scilex. MarketBeat recorded 6 mentions for Minerva Neurosciences and 0 mentions for Scilex. Minerva Neurosciences' average media sentiment score of 1.01 beat Scilex's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Scilex has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

Minerva Neurosciences has lower revenue, but higher earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Minerva Neurosciences has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

69.7% of Scilex shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

69.7% of Scilex shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alpha Cognition has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, Scilex has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

In the previous week, Alpha Cognition had 3 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Alpha Cognition and 0 mentions for Scilex. Alpha Cognition's average media sentiment score of 0.40 beat Scilex's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Alpha Cognition currently has a consensus price target of $16.00, indicating a potential upside of 77.56%. Given Alpha Cognition's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alpha Cognition is more favorable than Scilex.

Alpha Cognition has higher earnings, but lower revenue than Scilex. Alpha Cognition is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Alpha Cognition has a net margin of -232.23% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Alpha Cognition's return on equity.

Silverback Therapeutics has higher earnings, but lower revenue than Scilex. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Silverback Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Scilex'saverage media sentiment score.

Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Scilex has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.